A Dose Escalation, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of SAR650984 (Isatuximab) Administered Intravenously in Combination With Bortezomib - Based Regimens in Adult Patients With Newly Diagnosed Multiple Myeloma Non Eligible for Transplantation

Trial Profile

A Dose Escalation, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of SAR650984 (Isatuximab) Administered Intravenously in Combination With Bortezomib - Based Regimens in Adult Patients With Newly Diagnosed Multiple Myeloma Non Eligible for Transplantation

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2018

At a glance

  • Drugs Isatuximab (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CyBorDSAR
  • Sponsors Sanofi
  • Most Recent Events

    • 03 Apr 2018 Planned End Date changed from 18 Dec 2024 to 16 Jan 2025.
    • 03 Apr 2018 Planned primary completion date changed from 18 Dec 2024 to 16 Jan 2025.
    • 18 Dec 2017 Planned End Date changed from 18 Nov 2024 to 18 Dec 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top